Company
Headquarters: Cambridge, MA, United States
Employees: 30
CEO: Ms. Natalie C. Holles
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $0 |
| EBITDA | $-43,919,000 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |
Third Harmonic Bio Inc has the following listings and related stock indices.
Stock: NASDAQ: THRD wb_incandescent